Compare Aurora Cannabis Inc (ACB) vs Strategy Inc. (MSTR) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

MSTR stock trades at $97.36, down 3.38% on the day, with a bearish technical signal. The company reported a net loss of $3.85 billion in 2025, with a negative net income margin of -806.35%. Recent news highlights a strategic shift, including a $216 million Bitcoin sale to support preferred stock obligations, marking a departure from its previous 'never sell' stance. Analyst consensus remains largely positive with a $253 price target, but fundamental metrics show significant strain from persistent losses.

The outlook is clouded by deep profitability challenges and high volatility linked to digital asset holdings. Investment opportunity hinges on successful execution of the new capital management framework, but risks include further Bitcoin price declines and inability to achieve sustainable earnings. The stock's trajectory will depend heavily on balancing treasury management with core business performance.